Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer/Onyx Submit Nexavar sNDA For Liver Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Filing is based on halted Phase III trial showing overall survival of 44 percent in patients with hepatocellular carcinoma treated with sorafenib.

Related Content

Bayer/Onyx’s Nexavar Gets Liver Cancer Indication
As Nexavar’s Oncology Potential Grows, So Do Bayer’s Sales Predictions
Nexavar Long Term Opportunities Are In Breast, Lung Cancer, Onyx CEO Renton Says
Nexavar Survival Study In Asia-Pacific Patients With Liver Cancer Halted Early
Onyx Expects Early 2008 Launch For Nexavar In Liver Cancer
Bayer Puts Marketing Muscle Behind Yaz
Wyeth’s Torisel To Launch In July Following FDA Approval
Onyx/Bayer Expect 2008 Launch For Nexavar In Liver Cancer
Onyx/Bayer Expect 2008 Launch For Nexavar In Liver Cancer
Bayer/Onyx’ Nexavar Approved For Kidney Cancer





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts